---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-078511"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T16:44:49.752943+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Intellia board member Caroline Dorsa to resign effective June 15, 2023

## Summary
- Caroline Dorsa resigned from Intellia board and all committees effective June 15, 2023.
- She served as Audit Committee Chair and on the Compensation and Talent Development Committee.
- Resignation follows her appointment as chair of Biogen's board; no disagreement with Intellia.
- Company thanked Dorsa for her long, dedicated service.

## SEC filing metadata
- accession: 0001193125-23-078511
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312523078511/0001193125-23-078511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312523078511/d480012d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-078511
- JSON: https://secwatch.observer/filing/0001193125-23-078511.json
- Plain text: https://secwatch.observer/filing/0001193125-23-078511.txt

## Key facts
- Executive change
  Caroline Dorsa resigned as Director at Intellia Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On March 23, 2023, Caroline Dorsa notified Intellia Therapeutics, Inc. (the “Company”) of her intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective June 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312523078511/0001193125-23-078511-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.